DE2163054C3 - Lokalanästhetisches Mittel - Google Patents
Lokalanästhetisches MittelInfo
- Publication number
- DE2163054C3 DE2163054C3 DE2163054A DE2163054A DE2163054C3 DE 2163054 C3 DE2163054 C3 DE 2163054C3 DE 2163054 A DE2163054 A DE 2163054A DE 2163054 A DE2163054 A DE 2163054A DE 2163054 C3 DE2163054 C3 DE 2163054C3
- Authority
- DE
- Germany
- Prior art keywords
- saxitoxin
- stx
- lidocaine
- local anesthetic
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims description 20
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 claims description 35
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 claims description 35
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 22
- 229960004194 lidocaine Drugs 0.000 claims description 20
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 14
- 229960003920 cocaine Drugs 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical class NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 claims description 4
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 230000000903 blocking effect Effects 0.000 description 17
- 206010002091 Anaesthesia Diseases 0.000 description 10
- 230000037005 anaesthesia Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229960004919 procaine Drugs 0.000 description 9
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003444 anaesthetic effect Effects 0.000 description 7
- 229960005015 local anesthetics Drugs 0.000 description 7
- 210000003497 sciatic nerve Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 210000004706 scrotum Anatomy 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 229950007049 phenacaine Drugs 0.000 description 5
- 229960001896 pramocaine Drugs 0.000 description 5
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- -1 Aminoalkyl benzoates Chemical class 0.000 description 4
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 4
- 229960001747 cinchocaine Drugs 0.000 description 4
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 4
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000005526 vasoconstrictor agent Substances 0.000 description 4
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 3
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 229960003150 bupivacaine Drugs 0.000 description 3
- 229960005388 hexylcaine Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 229960002372 tetracaine Drugs 0.000 description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 3
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 229960003369 butacaine Drugs 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003502 oxybuprocaine Drugs 0.000 description 2
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001807 prilocaine Drugs 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229950003255 propoxycaine Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- CDJDGQRYHDBSKC-UHFFFAOYSA-N 2,3,4,5,6,7,8,9-octahydro-1h-purine Chemical group C1NCNC2NCNC21 CDJDGQRYHDBSKC-UHFFFAOYSA-N 0.000 description 1
- SLARELGEGUUVPI-UHFFFAOYSA-N 3-piperidin-1-ium-1-yl-1-(4-propoxyphenyl)propan-1-one;chloride Chemical compound Cl.C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 SLARELGEGUUVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000200139 Gonyaulax Species 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 241001238245 Saxidomus Species 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000004891 Shellfish Poisoning Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- WRMRXPASUROZGT-UHFFFAOYSA-N monoethylglycinexylidide Chemical compound CCNCC(=O)NC1=C(C)C=CC=C1C WRMRXPASUROZGT-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- BUJAGSGYPOAWEI-UHFFFAOYSA-N tocainide Chemical compound CC(N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10994271A | 1971-01-26 | 1971-01-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2163054A1 DE2163054A1 (de) | 1974-05-02 |
| DE2163054B2 DE2163054B2 (de) | 1978-06-01 |
| DE2163054C3 true DE2163054C3 (de) | 1979-02-01 |
Family
ID=22330411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2163054A Expired DE2163054C3 (de) | 1971-01-26 | 1971-12-18 | Lokalanästhetisches Mittel |
| DE19712163055 Pending DE2163055A1 (de) | 1971-01-26 | 1971-12-18 | Lokalanästhetisches Mittel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712163055 Pending DE2163055A1 (de) | 1971-01-26 | 1971-12-18 | Lokalanästhetisches Mittel |
Country Status (18)
| Country | Link |
|---|---|
| AT (2) | AT310938B (enExample) |
| AU (1) | AU465875B2 (enExample) |
| BE (2) | BE776769A (enExample) |
| BR (2) | BR7108429D0 (enExample) |
| CA (2) | CA986012A (enExample) |
| DD (2) | DD96144A5 (enExample) |
| DE (2) | DE2163054C3 (enExample) |
| DK (2) | DK130389B (enExample) |
| ES (2) | ES398108A1 (enExample) |
| FR (2) | FR2123277B1 (enExample) |
| GB (1) | GB1370904A (enExample) |
| HU (2) | HU162185B (enExample) |
| IE (2) | IE35937B1 (enExample) |
| LU (1) | LU64664A1 (enExample) |
| NL (2) | NL7117401A (enExample) |
| NO (2) | NO135891C (enExample) |
| SE (2) | SE391286B (enExample) |
| ZA (2) | ZA718326B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917894A (en) * | 1988-06-29 | 1990-04-17 | Beecham Inc. | Rapid-onset long-duration oral anesthetic composition |
| US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
| WO1998051290A2 (en) * | 1997-05-16 | 1998-11-19 | Children's Medical Center Corporation | Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent |
| RU2277097C1 (ru) * | 2004-12-27 | 2006-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Высокомеченный тритием дигидрохлорид [3h]сакситоксина |
| CN101563079B (zh) | 2006-03-27 | 2012-12-05 | 威克斯药业有限公司 | 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途 |
| US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
| KR20210062693A (ko) | 2013-03-15 | 2021-05-31 | 더 칠드런스 메디칼 센터 코포레이션 | 지속성 국소 마취용 네오삭시톡신 조합 제형 |
-
1971
- 1971-12-07 SE SE7115654A patent/SE391286B/xx unknown
- 1971-12-07 SE SE7115655A patent/SE391127B/xx unknown
- 1971-12-10 NO NO4557/71A patent/NO135891C/no unknown
- 1971-12-10 NO NO4558/71A patent/NO135892C/no unknown
- 1971-12-13 ZA ZA718326A patent/ZA718326B/xx unknown
- 1971-12-13 ZA ZA718327A patent/ZA718327B/xx unknown
- 1971-12-14 DK DK609571AA patent/DK130389B/da unknown
- 1971-12-16 HU HU71AA689A patent/HU162185B/hu unknown
- 1971-12-16 BE BE776769A patent/BE776769A/xx unknown
- 1971-12-16 BE BE776768A patent/BE776768A/xx unknown
- 1971-12-16 HU HUAA688A patent/HU162347B/hu unknown
- 1971-12-17 AT AT1084871A patent/AT310938B/de not_active IP Right Cessation
- 1971-12-17 DD DD159910A patent/DD96144A5/xx unknown
- 1971-12-17 DD DD159688A patent/DD96400A5/xx unknown
- 1971-12-17 FR FR7145542A patent/FR2123277B1/fr not_active Expired
- 1971-12-17 NL NL7117401A patent/NL7117401A/xx unknown
- 1971-12-17 NL NL7117404A patent/NL7117404A/xx not_active Application Discontinuation
- 1971-12-17 DK DK619971A patent/DK131606C/da active
- 1971-12-17 FR FR7145543A patent/FR2123278B1/fr not_active Expired
- 1971-12-17 CA CA130,378A patent/CA986012A/en not_active Expired
- 1971-12-17 AT AT1084971A patent/AT310939B/de not_active IP Right Cessation
- 1971-12-17 CA CA130,377A patent/CA983850A/en not_active Expired
- 1971-12-17 GB GB5865871A patent/GB1370904A/en not_active Expired
- 1971-12-18 DE DE2163054A patent/DE2163054C3/de not_active Expired
- 1971-12-18 ES ES398108A patent/ES398108A1/es not_active Expired
- 1971-12-18 ES ES398109A patent/ES398109A1/es not_active Expired
- 1971-12-18 DE DE19712163055 patent/DE2163055A1/de active Pending
- 1971-12-20 IE IE1611/71A patent/IE35937B1/xx unknown
- 1971-12-20 BR BR8429/71A patent/BR7108429D0/pt unknown
- 1971-12-20 IE IE1610/71A patent/IE35910B1/xx unknown
- 1971-12-20 BR BR8428/71A patent/BR7108428D0/pt unknown
- 1971-12-20 AU AU37100/71A patent/AU465875B2/en not_active Expired
-
1972
- 1972-01-26 LU LU64664D patent/LU64664A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69836352T2 (de) | Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen | |
| DE19781981B3 (de) | Neue Pestizidkombination | |
| DE69630947T2 (de) | Mittel zur schmerzbehandlung | |
| DE2331793C3 (enExample) | ||
| DE69329576T2 (de) | Präzipitation einer oder mehrerer aktiver verbindungen in situ | |
| DE69813839T2 (de) | Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| DE10197266T5 (de) | Verfahren zur örtlichen Betäubung und Schmerzstillung | |
| DE2163054C3 (de) | Lokalanästhetisches Mittel | |
| DE3130912A1 (de) | Analgetische arzneimittelkombination | |
| DE69430427T2 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| Hemsworth et al. | Preliminary pharmacological screening of styrylpyridine choline acetyltransferase inhibitors | |
| DE2427732A1 (de) | Mittel zum anaesthesieren von saeugetieren | |
| DE1220967B (de) | Verfahren zur Herstellung hochwirksamer lokalanaesthetischer Zubereitungen | |
| DE69233432T2 (de) | Verbesserte zusammensetzungen für die euthanasie | |
| WO1998043633A1 (de) | Lokalanästhetikum enthaltende gepufferte zusammensetzungen zur entzündungshemmung | |
| DE69118685T3 (de) | Zusammensetzungen für euthanasie | |
| DE2110537C3 (de) | N-Pyridyl-brenzschleimsäureamide, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| EP0845983A2 (de) | Pharmazeutisches präparat mit trypanoziden eigenschaften | |
| DE69923698T2 (de) | Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung | |
| DE2312134C2 (de) | Anthelmintikum | |
| DE69831959T2 (de) | Verwendung von (E)-metanicotinederivate als Analgetika | |
| DE1518443C (de) | 2-(2,6-Dimethoxyphenoxyäthyl)-aminomethyl-l,4-benzodioxan und dessen Hydrochlorid sowie Verfahren zu deren Herstellung | |
| DE2908127A1 (de) | Verwendung von inhibitoren des abbaus von enkephalinen und endorphinen bei der bekaempfung von schmerzzustaenden sowie zur herstellung pharmazeutischer zubereitungen und arzneimittel | |
| DE69524949T2 (de) | Eisen-Chelatierformulierung und Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| EHJ | Ceased/non-payment of the annual fee |